Benzinga | Jun 2, 2021 07:20AM EDT

BriaCell Provides Update On 12-Month Overall Survival Data On Previously-Disclosed Breast Cancer Patients; Top Responder Showed 100% Resolution of 'Eye-Bulging' Orbital Tumor

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell's lead candidate Bria-IMT(tm) as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA(r); manufactured by Merck & Co., Inc.) and Incyte's retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).

HLA-Typing Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body's immune response. BriaCell's immunotherapy treatment appears most effective when the patient's HLA-type matches with Bria-IMT(tm), allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test.

Tumor Grade BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell's treatment would be most effective.